Roivant Sciences Q3 2024 Earnings Report $11.57 +0.07 (+0.61%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Roivant Sciences EPS ResultsActual EPS-$0.26Consensus EPS -$0.33Beat/MissBeat by +$0.07One Year Ago EPSN/ARoivant Sciences Revenue ResultsActual Revenue$37.14 millionExpected Revenue$30.72 millionBeat/MissBeat by +$6.42 millionYoY Revenue GrowthN/ARoivant Sciences Announcement DetailsQuarterQ3 2024Date2/13/2024TimeN/AConference Call ResourcesSlide DeckPress ReleaseROIV Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Roivant Sciences Earnings HeadlinesRoivant Sciences (ROIV) Receives a Buy from Leerink PartnersDecember 18 at 5:22 AM | markets.businessinsider.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from AnalystsDecember 12, 2024 | americanbankingnews.comDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."December 21, 2024 | Banyan Hill Publishing (Ad)Roivant Sciences Stock Forecast: Bullish Trends and Key Performance MetricsDecember 6, 2024 | theglobeandmail.comRoivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage StudyDecember 4, 2024 | marketwatch.comRoivant to stop lung disease drug development after trial failureDecember 4, 2024 | msn.comSee More Roivant Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roivant Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roivant Sciences and other key companies, straight to your email. Email Address About Roivant SciencesRoivant Sciences (NASDAQ:ROIV), a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.View Roivant Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
